Corporate Banner
Satellite Banner
Technology Networks Header
Sunday, May 19, 2013
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
CIT Launches LeadScreen™, a New Range of Fast, Cost-effective Services for Drug Candidate Selection
Wednesday, March 30, 2011
Services offer an extensive array of tests designed to give an early evaluation of safety of drugs thought to have development potential.

PharmaDiagnostics Announces Three New Coupling Methods for its SoPRano™ Label-Free Platform
Sunday, March 20, 2011
Three new methods expand options for coupling proteins to gold nanoparticles, broaden applicability.

Hepregen Corporation Presents Results of Liver Toxicity Study at Annual Meeting of the Society of Toxicology
Friday, March 11, 2011
Hepregen's microliver platform, HepatoPac™, provides increased confidence in drug development to impact patient safety.

New Robot System to Test 10,000 Chemicals for Toxicity
Friday, March 11, 2011
NIH has unveiled a new high-speed robot screening system that marks the beginning of a new phase of an ongoing collaboration, referred to as Tox21.

Sigma® Life Science adds 1,400 Cell Lines to its U.S. Portfolio of ECACC® Products
Thursday, March 10, 2011
Sigma Life Science has announced the addition of 1,400 new European Collection of Cell Culture (ECACC) cell lines to its collection of cell line cultures and services.

Thermo Fisher Scientific Introduces Liver Toxicity Testing Solution for Drug Development
Tuesday, March 08, 2011
Helps pharmaceutical companies improve productivity by assessing the risk of liver toxicity earlier in the development process.

Roche and RainDance Technologies Join Forces in Targeted Sequencing to Advance ADME Research
Tuesday, March 08, 2011
RainDance Technologies, Inc., and 454 Life Sciences, a Roche Company announces collaboration for the development and commercialization of a targeted next-generation sequencing (NGS) solution for simple and cost-effective investigation of drug ADME.

Redefine Your Absorbance Assays With a Free SPECTROstar Nano Microplate Reader From BMG Labtech!
Monday, March 07, 2011
To celebrate the launch of the new SPECTROstar Nano, BMG Labtech is offering the chance to receive one of five free SPECTROstar Nano absorbance microplate readers which include an ultra-fast spectrometer to instantaneously capture a full UV/Vis spectrum in microplates, cuvettes and low volume samples.

BioTek Offers Peristaltic Pump Cassette Recalibration Options
Thursday, February 24, 2011
BioTek now offers three options to customers requiring peristaltic pump cassette recalibration for MultiFlo™ Microplate Dispenser, EL406™ Combination Washer Dispenser and MicroFlo™ Select Microplate Dispenser.

<< 9 10 11 12 13 14 15 >>
Showing Results 111 - 120 of 581
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Get The App
Go to LabTube.tv
Go to ePosters.net